FDA nears deadline on closely-watched melanoma drug

All eyes are on the FDA as regulators face a Saturday deadline for their decision on Bristol-Myers Squibb's melanoma drug ipilimumab. With an average extended survival of four months, the therapy presents a significant advance for victims with advanced cases. Several analysts expect an approval, but the FDA can be hard to read even at this stage of the game. Report